Showing 3791-3800 of 5956 results for "".
- The European Commission (EC) Approves Eylea 8 mg for Extended Treatment Intervals of Up to 6 Monthshttps://modernod.com/news/the-european-commission-ec-approves-eylea-8-mg-for-extended-treatment-intervals-of-up-to-6-months/2482867/The European Commission (EC) has granted a label extension in the European Union (EU) for Eylea 8 mg with extended treatment intervals of up to 6 months for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Eylea 8 mg was previously
- Ashvattha Therapeutics Presents Positive Interim Phase 2 Results for Subcutaneous Migaldendranib Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-presents-positive-interim-phase-2-results-for-subcutaneous-migaldendranib-treatment-for-dme-and-wet-amd/2482864/Ashvattha Therapeutics announced interim results from its ongoing phase 2 study of subcutaneous (subQ) migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and wet age-related macular degeneration (AMD). The data were presented at the MaculArt Meeting, June 29–July 1, 2025
- Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congresshttps://modernod.com/news/qlaris-bio-to-present-new-clinical-and-preclinical-data-on-qls-111-at-2025-world-glaucoma-congress/2482859/Qlaris Bio announced that new data from studies of its lead investigational compound QLS-111 will be presented at the 2025 World Glaucoma Congress (WGC). This will include an oral presentation on clinical data from the recently completed QC-111-201 “Osprey” and QC-111-203 “
- New York Eye and Ear Infirmary of Mount Sinai Opens First Comprehensive Center for Refractive Solutions in New Yorkhttps://modernod.com/news/new-york-eye-and-ear-infirmary-of-mount-sinai-opens-first-comprehensive-center-for-refractive-solutions-in-new-york/2482855/The New York Eye and Ear Infirmary of Mount Sinai (NYEE) has announced the launch of the Center for Refractive Solutions, a facility dedicated to comprehensive vision correction services. Located at 310 East 14th Street in Lower Manhattan, the newly renovated
- PolyActiva Appoints Jerry St. Peter as CEO; Secures Financing to Advance Prezia Technology Platformhttps://modernod.com/news/polyactiva-appoints-jerry-st-peter-as-ceo-secures-financing-to-advance-prezia-technology-platform/2482854/PolyActiva announced two milestones in its next phase of growth: the appointment of biopharmaceutical executive Jerry St. Peter as CEO and board director, and the successful close of a $25M Series C funding round led by an Australian Sovereign Wealth Fund
- Johnson & Johnson Launches Tecnis Odyssey IOL in Europe, the Middle East, and Canadahttps://modernod.com/news/johnson-johnson-launches-tecnis-odyssey-iol-in-europe-the-middle-east-and-canada/2482853/Johnson & Johnson announced that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of Tecnis Odyssey IOL in Europe, the Middle East, and Canada. According to J&J, the new full visual range IOL offers high-quality and c
- Heidelberg Engineering Launches ZinserLab Innovation Hub to Accelerate Imaging Innovation in Eye Carehttps://modernod.com/news/heidelberg-engineering-launches-zinserlab-innovation-hub-to-accelerate-imaging-innovation-in-eye-care/2482848/Heidelberg Engineering announced the launch of the ZinserLab, an innovation hub that aims to accelerate the development of imaging technologies with clinical value for eye care. The hub is named in honor of Dr. Gerhard Zinser, the
- Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Datahttps://modernod.com/news/ashvattha-therapeutics-to-present-phase-2-dme-and-wet-amd-data/2482846/Ashvattha Therapeutics announced it will present new data focusing on previously reported phase 2 clinical data on migaldendranib, its investigational subcutaneous therapy for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which could offer a
- SpliceBio Secures $135M Series B to Advance Gene Therapy for Stargardt Diseasehttps://modernod.com/news/splicebio-secures-135m-series-b-to-advance-gene-therapy-for-stargardt-disease/2482845/SpliceBio announced the closing of a $135 million Series B financing round to support the clinical advancement of SpliceBio’s lead gene therapy candidate, SB-007, for Stargardt disease. There are currently no approved treatments for the disease, which is
- Gore Launches 0.5 mL Silicone-Free Gore Improject Plunger for Ophthalmic Pre-Filled Syringeshttps://modernod.com/news/gore-launches-05-ml-silicone-free-gore-improject-plunger-for-ophthalmic-pre-filled-syringes/2482843/W. L. Gore & Associates announced the commercial launch of the 0.5 mL silicone-free Gore Improject syringe plunger. The new offering, made within the company's PharmBIO business, is designed for prefilled syringes used in various applications, including ophthalmic intr